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The b1-adrenoceptor (b1AR) is the site of action of
beta blockers used in the treatment of cardiac-
related illnesses. Two beta blockers, carvedilol and
bucindolol, show distinctive activities compared to
other beta blockers and have been proposed as
treatments tailored to the Arg/Gly3898.56 polymor-
phism of the human b1AR. Both carvedilol and bucin-
dolol are classified as biased agonists, because they
stimulate G protein-independent signaling, while
acting as either inverse or partial agonists of the G
protein pathway. We have determined the crystal
structures of a thermostabilized avian b1AR mutant
bound to bucindolol and to carvedilol at 3.2 and
2.3 A˚ resolution, respectively. In comparison to other
beta blockers, bucindolol and carvedilol interact with
additional residues, in extracellular loop 2 and trans-
membrane helix 7, which may promote G protein-
independent signaling. The structures also suggest
that there may be a structural explanation for the
pharmacological differences arising from the Arg/
Gly3898.56 polymorphism.
INTRODUCTION
The seven-transmembrane-helix receptors (7TMRs) comprise
a large and diverse family of cell-surface receptors that on
agonist binding can bind and activate a G protein and subse-
quently initiate diverse signaling events. Some ligands also stim-
ulate G protein-independent pathways (Pierce et al., 2002);
unless otherwise stated, the terms ‘‘agonist’’ and ‘‘antagonist,’’
etc. refer to the G protein-coupled pathway (see Box 1 for phar-
macological definitions). The 7TMRs are the largest single class
of drug target (Wise et al., 2002), and the b-adrenoceptors (bARs)
are the targets of beta blockers (antagonists of the G protein-
coupled pathway) in the treatment of heart failure, as well as
agonists used in asthma therapies. Recent structures of both
the b1-adrenoceptor (b1AR) and the b2-adrenoceptor (b2AR)
have led to an understanding of the molecular characteristics
that define an agonist compared to an inverse agonist and how
an agonist promotes the activation of a G protein (Cherezov
et al., 2007; Hanson et al., 2008; Moukhametzianov et al.,
2011; Wacker et al., 2010; Warne et al., 2008, 2011). The struc-Structure 20tures of the inactive states (R) of bARs when bound to antago-
nists are very similar, although there are some differences in
the region of the ‘‘ionic lock’’ depending on whether the salt
bridge between Arg3.50 and Glu6.30 is present or not (Moukha-
metzianov et al., 2011) (superscripts refer to the Ballesteros
Weinstein nomenclature (Ballesteros and Weinstein, 1995)).
When full agonists bind to the R state, the most significant
effects are the contraction of the binding pocket and the change
in rotamer conformation of Ser5.46, implying that these are
a prerequisite to the attainment of the activated state (R*) that
can couple to G proteins (Warne et al., 2011). In contrast to
agonists, partial agonists apparently do not form a hydrogen
bond to Ser5.46, which explains their decreased efficacy (Warne
et al., 2011). The structure of b2AR bound to either a G protein
mimetic or Gs shows that the agonists bind to R* in the same
manner as to the R state and that the intracellular regions of
helices 5 and 6 move by 10-14 A˚ upon activation (Rasmussen
et al., 2011a; Rasmussen et al., 2011b). The challenge over the
coming years is to relate the structures of the bARs bound
to various ligands and the pharmacological effects of drugs
targeting bARs in humans, particularly where the ligands also
stimulate G protein-independent pathways, such as through
interactions with arrestin.
In the classical view of 7TMR-ligand interactions, agonists
bind to receptors and stimulate the activity of specific G proteins
to varying degrees, whereas inverse agonists block the effects of
agonist activation and also inhibit constitutive signaling. In this
view, sometimes termed linear efficacy, the signaling processes
associated with a drug’s activity are in proportion to its efficacy
and therefore its position on the scale of effects ranging from that
of a full to an inverse agonist of a G protein, as was shown in early
studies on the b2AR (Benovic et al., 1988). It is now clear that this
is an oversimplification, and the more recent concept of biased
agonist function has evolved in response to a body of evidence
that shows that 7TMRs can interact directly with other signaling
partners, for example, arrestin. These alternative G protein-inde-
pendent signaling pathways can be selectively stimulated along-
side G protein activation, and a ligand’s efficacy can be ‘‘biased’’
more or less to different pathways (Rajagopal et al., 2010; Violin
and Lefkowitz, 2007). In addition to the implied requirement for
distinct conformational states to explain these receptor activities
(Kenakin, 2001), there is also a growing realization that existing
drugs that target 7TMRs may have more complex effects than
first realized, and that the concept of ligand bias may therefore
allow the development of more effective therapies (Whalen
et al., 2011)., 841–849, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 841
Box 1. Pharmacological Definitions
Agonist. A ligand that binds to and activates a receptor and
elicits a physiological response. The endogenous agonist for
the b1AR is noradrenaline, which is a full agonist that elicits
the maximal response for the receptor in activating a G
protein.
Constitutive or basal activity. Physiological response that
occurs in the absence of any receptor-activating ligand
due to a fraction of the receptor being in an activating
conformation.
Inverse agonist. A ligand that binds to a receptor and inhibits
or eliminates, in the case of a full inverse agonist, the basal or
constitutive activity of a receptor.
Partial agonist or partial inverse agonist. Ligands that elicit
only a partial response when compared to either a full agonist
or a full inverse agonist, respectively.
Antagonist. Any ligand that blocks binding of endogenous
agonists to the receptor, thereby modulating receptor activity.
A general term that encompasses ligands that may be inverse
agonists, partial agonists, or neutral in effect.
Beta blockers. Term for antagonists of bARs when used in
a therapeutic setting.
Biased agonist. A ligand that binds to a receptor and signals
to a variable extent through both G protein-dependent and G
protein-independent pathways. A ligand may be ‘‘weakly
biased,’’ i.e., signaling is mainly via G proteins or ‘‘perfectly
biased,’’ i.e., the ligand is an inverse agonist of the G
protein-coupled pathway as well as an agonist of the G
protein-independent pathways.
Note. The categorization of ligands can be dependent on the
type of assay used, the cell type in which the receptor has
been expressed, expression levels, and the sensitivity and
dynamic range of the assay used to detect downstream
signaling events.
Structure
Biased Agonist-Bound b1-Adrenoceptor StructuresCarvedilol and bucindolol are both beta blockers (antagonists)
that target b1AR (see Figure 1 for the structures of ligands) and
can also bind to b2AR. However, both bucindolol and carvedilol
have also been shown to stimulate non-G protein-coupled path-
ways of bARs (i.e., they are biased agonists). With the human
b1AR, bucindolol has been found to act as a partial agonist of
the G protein-signaling pathway as well as an agonist of the
mitogen-activated protein kinase (MAPK) pathway through a G
protein-independent mechanism (Galandrin et al., 2008). This
suggests that bucindolol can induce a signaling conformation
of b1AR that is distinct from both conventional (G protein) antag-
onist-bound and agonist-bound states (Galandrin et al., 2008).
All conventional bAR agonists can enhance arrestin-mediated
signaling as a functional consequence of their activation of the
G protein-signaling pathway (Drake et al., 2008; Wisler et al.,
2007). However, carvedilol is an inverse agonist of G protein
signaling, but it stimulates arrestin-mediated signaling pathways
of both human b2AR and mouse b1AR independently of G
protein-mediated signaling (Kim et al., 2008; Wisler et al.,
2007). Because of these unique properties, its interactions with
bARs will be of interest as it has been suggested that carvedilol
could be a prototype for the design of a new generation of842 Structure 20, 841–849, May 9, 2012 ª2012 Elsevier Ltd All rightstherapeutic agents that could stimulate arrestin-dependent
signaling, with potentially increased cardioprotective effects, to
a greater extent than current beta blockers (Nobles et al.,
2011; Noma et al., 2007; Wisler et al., 2007).
The major structural changes that result in binding and activa-
tion of a G protein by a 7TMR include large outward movements
of transmembrane helices 5 and 6 (Rasmussen et al., 2011b),
but the receptor conformational changes that might promote
arrestin-mediated signaling or signaling through other G
protein-independent pathways in preference to G protein activa-
tion are at present unknown. In the case of the b2AR, ligands that
stimulate arrestin signaling are thought to cause conformational
changes at the receptor’s C terminus, and these might promote
phosphorylation and facilitate interactions with regulatory
proteins such as arrestin (Granier et al., 2007). Small increases
in phosphorylation levels of the b2AR C terminus have been
demonstrated for some arrestin-biased agonists, including
carvedilol (Drake et al., 2008), and the resulting pattern of
phosphorylation is distinct from that promoted in response to
stimulation with the nonbiased agonist, isoprenaline (Nobles
et al., 2011).
Bucindolol and carvedilol are clearly of interest in relation to
their role in the activation of non-G protein-mediated signaling
pathways, and, in addition, they are also being studied with
respect to two isoforms of human b1AR in the treatment of
congestive heart failure. A common single nucleotide polymor-
phism occurs in amphipathic helix 8 (H8) of human b1AR, where
Arg3898.56 is substituted by Gly in 20%–40% of the population
depending on ethnicity (Maqbool et al., 1999). The Arg/Gly389
polymorphism results in a significant variation in G protein acti-
vation, with b1AR-Arg389 having a slightly higher basal activity
and a 3-fold increased adenylyl cyclase activity on stimulation
with the nonbiased agonist isoprenaline compared to b1AR-
Gly389 (Mason et al., 1999). Both carvedilol and bucindolol
have been shown to be more effective than other beta blockers
as inverse agonists of b1AR-Arg389 (Liggett et al., 2006; Rochais
et al., 2007), findings which were initially heralded as a starting
point for personalized therapies in heart failure (DeGeorge and
Koch, 2007; Pleger and Koch, 2006).
In order to elucidate the interactions of these ligands with the
receptor as a foundation for further studies of signaling with
biased agonists, and to determine possible reasons for the
enhanced activities of the ligands on b1AR-Arg389, we have
determined the cocrystal structures of a thermostabilized avian
b1AR with bucindolol and carvedilol.
RESULTS AND DISCUSSION
Structures of b1AR Bound to Bucindolol and Carvedilol
The avian b1AR was modified to allow crystallization by the
removal of flexible regions at the N terminus, C terminus, and
in cytoplasmic loop 3, and the introduction of 8 point mutations
(see Experimental Procedures), to give the construct b1AR44-
m23. Six of the point mutations result in thermostabilization of
b1AR (Serrano-Vega et al., 2008), which allows crystallization in
short-chain detergents (Warne et al., 2008). A consequence of
thermostabilization is that the receptor is preferentially in the
antagonist-bound state (R) (Serrano-Vega et al., 2008), although
b1AR-m23 is capable of binding agonists with a similar rankreserved
Figure 1. Structures of bAR Ligands Discussed in
the Main Text
Highlighted regions of the ligands are either conserved
with the agonist adrenaline (blue) or are conserved among
antagonists (red).
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Biased Agonist-Bound b1-Adrenoceptor Structuresorder of potency to the wild-type receptor and can couple effi-
ciently to G proteins (Baker et al., 2011). It is not feasible to
perform crystallography on human b1AR due to its extreme
instability (Serrano-Vega and Tate, 2009), but the high sequence
identity between the receptors (82%) in the transmembrane
domains and loop regions (except most of cytoplasmic loop 3)
shows b1AR-m23 is an excellent model for studying ligand-Figure 2. Structure of b1-Adrenoceptor bound to Carvedilol
(A) The structure of b1AR bound to carvedilol, with the receptor monomer in rainbow coloration with t
is shown in space-filling representation (C, gray; O, red; N, blue). The intracellular side is at the botto
(B) Omit map (2Fo-Fc) density for carvedilol (contour level 1.3 s).
(C) Omit map (2Fo-Fc) density for bucindolol (contour level 1.0 s).
(D–F) Alignment of b1AR structures was performed and the superposition of the ligands are depicted.
PDB code 2VT4). (E) Alignment of bucindolol (pink) with carvedilol (green). (F) Alignment of carvedilo
Structure 20, 841–849, May 9receptor interactions. Indeed, crystal structures
of b1AR-m23 (Warne et al., 2008) and b2AR-T4L
(Cherezov et al., 2007) show high similarity in the
transmembrane domains (rmsd 0.7 A˚) and
especially in the region of the ligand binding
pocket (rmsd of 0.25 A˚ for 78 Ca atoms). None
of the mutations in b1AR-m23 are in the ligand
binding pocket and none of the sites of
the mutations show a conformational change
when comparing the structures of b1AR-m23
and b2AR-T4L.
Receptors were expressed, purified and crys-
tallized as previously described. The cocrystal
structures of b1AR44-m23 bound to either
bucindolol or carvedilol were solved at resolu-tions of 3.2 and 2.3 A˚, respectively (Figure 2 and Table 1). Overall
the two structures are very similar (RMSD of Ca positions <0.5 A˚)
to the inactive state structure of b1AR (Protein Data Bank [PDB]
2VT4) with bound cyanopindolol (Warne et al., 2008). The lack
of any significant conformational change at the ends of helices
5 and 6 is consistent with previous R-state structures of
b1AR-m23 with bound antagonists and agonists and of b2ARhe N terminus in blue and the C terminus in red. Carvedilol
m of the figure.
(D) Alignment of bucindolol (pink) and cyanopindolol (gray,
l (green) with carazolol (yellow, PDB code 2YCW).
, 2012 ª2012 Elsevier Ltd All rights reserved 843
Table 1. Data Processing, Refinement, and Evaluation Statistics
b44-m23 +
Bucindolol
b44-m23 +
Carvedilol
Space group P21 P21
Cell dimensions a, b, c (A˚), b (o) 89.8, 60.7,
107.8, 110.8
90.1, 62.2,
100.9, 109.2
Data Processing
Resolution (A˚) 52.1–3.2 52.1–2.3
Rmergea 0.102 (0.596) 0.099 (0.593)
<I/s(I)>a 9.9 (2.5) 11.3 (2.1)
Completeness (%)a 95.9 (86.5) 99.8 (99.1)
Multiplicitya 5.3 (5.4) 6.2 (4.0)
Wilson B factor (A˚2) 103.6 37.5
Refinement
Total number of reflections 16,557 44,731
Total number of atoms 4,673 4,962
Number of waters 13 100
Number of detergent molecules 5 12
Number of sodium ions 0 2
Rwork
b,c 0.242 (0.350) 0.202 (0.288)
Rfree
c,d 0.279 (0.384) 0.240 (0.315)
Rmsd bonds (A˚) 0.005 0.012
Rmsd angles (o) 0.984 1.39
Mean atomic B factor (A˚2) 92.7 39.2
Estimated coordinate error (A˚) 0.35 0.125
Ramachandran plot favored (%)e 98.2 98.1
Ramachandran plot outliers (%)e 0 0
aValues in parentheses are for the highest resolution bin (A˚) (bucindolol,
3.37–3.2; carvedilol, 2.42–2.30).
bNumber of reflections used to calculate Rwork (bucindolol, 15,659
[94.9%]; carvedilol, 42,352 [95.0%]).
cValues in parentheses are for the highest resolution bin for refinement (A˚)
(bucindolol, 3.28–3.20; carvedilol, 2.36–2.30).
dNumber of reflections from a randomly selected subset used to calcu-
late Rfree (bucindolol, 898 [5.1%]; carvedilol 2,378 [5.0%]).
eFigures obtained using MolProbity (Davis et al., 2007).
Figure 3. Structures of the Ligand Binding Pocket
b1AR-m23 is depicted as a cartoon (gray) viewed from the extracellular surface
with specific side chains (C, green; N, red; O, blue) depicted making potential
hydrogen bonds (red dashed lines) to the ligand, as well as the interhelical
potential hydrogen bond between Ser2125.43 and Asn3106.55. The ligand
coloring scheme is C, yellow; N, red; O, blue.
(A) Bucindolol.
(B) Carvedilol. Note the alternative rotamer conformation of Asn3106.55
depicted in the carvedilol-bound structure in which the amide oxygen faces
toward H5. In this configuration a potential steric clash with the ligand is
avoided, this conformation could be dependent on the nature of the ligand.
Structure
Biased Agonist-Bound b1-Adrenoceptor Structurescomplexed with either antagonists or with a covalently bound
agonist. Thus, the structures presented here of b1AR bound to
either bucindolol or carvedilol show in detail the ligand-receptor
interactions (see below), but they do not define a new conforma-
tion of the receptor involved in G protein-independent signaling.
It is likely that a complex of a phosphorylated bAR with arrestin
will be required to fully understand the conformational change
induced by the binding of biased agonists, because the signaling
conformation of the receptor that allows arrestin binding is likely
to be transient. This is consistent with the observation that the
binding of a G protein or analog was required to obtain the
structure of an R* state of b2AR (Rasmussen et al., 2011a,
2011b), while the structure of b2AR bound to a covalent agonist
is in the R state (Rosenbaum et al., 2011). Therefore, it seems
unlikely that any key conformational changes are missing due
to the presence of the thermostabilizing mutations. In contrast
to the bARs, some receptors evince considerable conforma-
tional changes when crystallized in the presence of an agonist.844 Structure 20, 841–849, May 9, 2012 ª2012 Elsevier Ltd All rightsFor example, the structure of the adenosine A2A receptor bound
to an agonist is clearly in an R*-like state, without the requirement
for binding a G protein or G protein mimetic (Lebon et al., 2011;
Xu et al., 2011).
Ligand Binding in the Catecholamine Binding Pocket
The structures of bAR ligands are often very similar, particularly
in the region of the secondary amine and b-hydroxyl groups
and these are also conserved in bucindolol and carvedilol
(Figure 1). The cocrystal structures show that their secondary
amine and b-hydroxyl groups form potential hydrogen bonds
with Asp1213.32 and Asn3297.39 and their ‘‘head groups’’ (equiv-
alent to the catechol moiety in adrenaline) occupy a position
adjacent to H5 (Figure 3). Thus, both ligands exhibit the same
general mode of binding observed for other bAR antagonistsreserved
Figure 4. Key Receptor-Ligand Interactions between Bucindolol,
Carvedilol, and b1AR
Receptor structures are shown in cartoon representation as viewed in the
membrane plane with the three helices obscuring the binding site removed for
clarity and the remaining helices labeled: (A and B) monomer A of the
bucindolol complex; (C and D) monomer B of the carvedilol complex. Amino
acid residues within 3.9 A˚ of the ligands (yellow) are depicted in stick repre-
sentation; green, residues with previously known ligand interactions; orange,
residues in the extended ligand binding pocket interacting with either the
indole or methoxyphenoxy substituents on the ligands. Atoms are colored
accordingly; C, yellow, green, orange; O, red; N, blue. Potential hydrogen
bonds are shown as red dashes. Carvedilol makes a polar contact with EL2
mediated by a bridging water molecule (red sphere labeled w; B-factor 42 A˚2).
The disulphide bond (labeled S-S) between Cys199 on EL2 and Cys1143.25
on H3 is shown in (B) and (D). For a full list of receptor-ligand interactions
and Ballesteros-Weinstein nomenclature, see Table 2.
Structure
Biased Agonist-Bound b1-Adrenoceptor Structurescocrystallized with either b1AR or b2AR (Cherezov et al., 2007;
Hanson et al., 2008; Moukhametzianov et al., 2011; Wacker
et al., 2010; Warne et al., 2008).
Previously, we showed that binding of a full agonist to b1AR
resulted in three differences in receptor conformation compared
to when an antagonist was bound, namely the rotamer confor-
mation changes of Ser2125.43 and Ser2155.46, and a contraction
of the ligand binding pocket. Comparison of the structures of
b1AR bound to bucindolol and carvedilol with the previously
determined structures shows that the rotamer configuration of
Ser2155.46 allows the formation of an interhelical hydrogen
bond with H3, as seen in the structures with bound partial
agonists, but not with bound full agonists where Ser2155.46
forms a hydrogen bond directly to the ligand (Figure 4). However,
the configuration of Ser2125.43 is similar to that seen in the
agonist-bound structures where it makes a potential hydrogen
bond to Asn3106.55. A recently determined structure of b1AR
with cyanopindolol bound in lipidic meso phase at a resolution
of 2.1 A˚ (J.L. Miller and C.G.T., unpublished data) also shows
this alternative rotamer conformation of Ser2125.43 comparedStructure 20to the previous structure of cyanopindolol-bound b1AR deter-
mined in detergent (Warne et al., 2008); these data suggest
that Ser2125.43 can also be in this alternative conformation with
an antagonist bound, and the configuration of Ser2125.43 is
therefore unlikely to represent an agonist-specific conformation.
Both the bucindolol and carvedilol bound structures also do not
exhibit the contraction of the binding pocket observed in the
structures with full and partial agonists bound. It is therefore
clear that the ligands do not induce the initial conformational
changes in the receptor that are characteristic of agonists that
activate G proteins. Bucindolol has been variously reported as
being either an inverse agonist or partial agonist of the b1AR, de-
pending on the system or tissue studied (Andreka et al., 2002;
Engelhardt et al., 2001; Galandrin et al., 2008; Maack et al.,
2000, 2003). However, in both bucindolol-bound and carvedi-
lol-bound b1AR structures, the characteristic rotamer conforma-
tion change of Ser2155.46 observed in structures with a full
agonist bound is sterically blocked by the ligand, which is a char-
acteristic of bAR inverse agonists (Warne et al., 2011).
Ligand Binding in the Extended Ligand Binding Pocket
Both bucindolol and carvedilol, unlike all other antagonists
cocrystallized with bARs, have bulky aromatic substituents at
their amine ends that make additional contacts in the extended
ligand binding pocket composed of residues in helices 2, 3,
and 7 and extracellular loop 2 (Figure 4). The additional contacts
are detailed along with all other ligand-receptor contacts in
Table 2. It therefore seems logical to propose that the ability of
bucindolol and carvedilol to stimulate G protein-independent
signaling resides in the extensions in the tail region of the ligand
that are absent from all other antagonists. However, it is difficult
to say how these additional contacts might promote G protein-
independent signaling, because the conformations that might
finally promote the binding of arrestin or other signaling proteins
are currently unknown. However, it seems plausible that the
additional contacts may result in an increased probability of
subtle conformational changes that might be transmitted to the
receptor’s C terminus, where phosphorylation byGPCR-specific
kinases promotes binding of arrestin and signaling (Granier et al.,
2007; Nobles et al., 2011).
Bias of conventional G protein agonists of bARs toward the
arrestin-signaling pathway has been investigated and methods
to discern levels of G protein-independent activity that are
relatively low compared to the dominant G protein-signaling
activity are being developed. This has led to the categorization
of a number of ligands that can activate both G protein-coupled
and G protein-independent pathways, but to different extents
(Rajagopal et al., 2011). However, currently there is not
a comprehensive list of the propensity of all bAR ligands for
inducing signaling via G protein-independent pathways. So far,
bias toward arrestin signaling among conventional G protein
agonists has only been detected in ligands with either ethyl
substitutions at the Ca, or amine-end substituents, such as
those present in bucindolol and carvedilol (Drake et al., 2008;
Rajagopal et al., 2011). Of the conventional G protein agonists
that have been cocrystallized previously with either b1AR or
b2AR, dobutamine, isoprenaline and salbutamol have been
identified as nonbiased agonists of the b2AR (Rajagopal et al.,
2011). The structure of b1AR bound to carmoterol has been, 841–849, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 845
Table 2. Amino Acid Side-Chain Contacts between b1AR and Ligands
Amino Acid
Residue
B-W
Number
Secondary
Structure
Bucindolol
Monomer A
Carvedilol
Monomer B
Carazolol 2YCW
Monomer A
Cyanopindolol 2VT4
Monomer B
Leu101 2.64 H2 — v der W — —
Trp117 3.28 H3 v der W v der W v der W v der W
Thr118 3.29 H3 v der W — — v der W
Asp121 3.32 H3 H-bond H-bond H-bond H-bond
Val122 3.33 H3 v der W v der W v der W v der W
Val125 3.36 H3 v der W v der W v der W —
Cys199 — EL2 H-bond — — —
Asp200 — EL2 v der W v der W — —
Phe201 — EL2 v der W v der W
(H-bond via water)
v der W v der W
Thr203 — EL2 — — — Polar
Tyr207 5.38 H5 — v der W v der W —
Ala208 5.39 H5 — — — v der W
Ser211 5.42 H5 v der W H-bond H-bond H-bond
Ser215 5.46 H5 v der W v der W v der W v der W
Trp303 6.48 H6 v der W v der W v der W v der W
Phe306 6.51 H6 v der W v der W v der W v der W
Phe307 6.52 H6 v der W v der W v der W v der W
Asn310 6.55 H6 v der W v der W v der W H-bond
Phe325 7.35 H7 v der W — — —
Val326 7.36 H7 v der W — — —
Asn329 7.39 H7 H-bond H-bond H-bond H-bond
Trp330 7.40 H7 — v der W — —
Tyr333 7.43 H7 v der W v der W v der W v der W
Structure
Biased Agonist-Bound b1-Adrenoceptor Structuresdetermined (Warne et al., 2011), but this ligand has not been
tested for signaling bias. However, formoterol, which is weakly
arrestin biased, is structurally identical to carmoterol apart
from a minor difference in its head group; both ligands have
the same methoxyphenyl amine end extension (see Figure 1
for the structures) (Rajagopal et al., 2010). The cocrystal struc-
ture of carmoterol with the b1AR indicates additional interactions
of the methoxyphenyl group with extracellular loop 2 (EL2) as
well as H7, and NMR data suggest that formoterol’s methoxy-
phenyl group also interacts with residues on EL2 of the b2AR
(Bokoch et al., 2010). Thus, of the three ligands with amine-
end extensions that bind in the extended ligand binding pocket
for which there are cocrystal structures and that have been
examined for bias, bucindolol and carvedilol are biased
agonists, whereas dobutamine is not. As in all probability,
formoterol, which also shows weak arrestin bias also binds to
EL2, one structural feature that may correlate with agonist bias
is that bucindolol, carvedilol, and most likely formoterol all
interact with EL2, whereas dobutamine does not. Whether this
observation extends to other biased agonists will require further
detailed characterization of more bAR ligands with both b1AR
and b2AR rather than just a limited few.
While this manuscript was in review, a related manuscript
appeared (Liu et al., 2012), which detailed 19F-NMR studies on
b2AR bound to various ligands. Specific Cys residues in deter-
gent-solubilized, purified b2AR were covalently modified with
trifluoroethanethiol and then 19F spectra were collected in the846 Structure 20, 841–849, May 9, 2012 ª2012 Elsevier Ltd All rightspresence of inverse agonists, agonists, or biased agonists. The
most significant difference observed when an inverse agonist
was bound compared to when a biased agonist was bound
was a change in the spectrum of 19F-labeled Cys327; this
residue is in the short linker between H7 and H8. These data indi-
cate that the environment around Cys327 is different when
a biased agonist is bound compared to when an inverse agonist
is bound, which is consistent with the interpretation of the
structural data presented here and previous biochemical data
(Granier et al., 2007; Nobles et al., 2011).
Understanding the Effects of the Arg389Gly
Polymorphism in Human b1AR
The high-resolution of the b1AR-carvedilol complex fortuitously
also allows us to suggest a mechanism for the difference in phar-
macology in the frequently occurring Arg389Gly polymorphism
of the human b1AR. The more common b1AR-Arg389 variant
has a slightly higher basal G protein activity and a 3-fold increase
in agonist response compared to the b1AR-Gly389 variant
(Mason et al., 1999). It has been suggested that the affected
residue is in an area important for G protein coupling (Mason
et al., 1999), but it is now clear from the structure of the
b2AR-Gs complex that this is not the case (Rasmussen et al.,
2011b). Therefore, the differences in pharmacology between
the Arg/Gly variants must lie within the receptor itself.
The human b1AR residue affected by the polymorphism,
Arg3898.56, is equivalent to Arg3558.56 in the turkey b1AR and itreserved
Figure 5. Interactions between Amphipathic H8
and H1
(A) The structure of carvedilol-bound b1AR-m23 is shown
as viewed from the cytoplasmic surface in rainbow
coloration (N terminus blue, C terminus red) and the
helices labeled accordingly (H1-H8).
(B) Region depicting the potential hydrogen bonds (red
dashed lines) between side chains in H1 and H8. The
electron density for Arg355 suggests that alternative
rotamer conformations are present, but the conformation
depicted represents the most favored.
Structure
Biased Agonist-Bound b1-Adrenoceptor Structuresis located on H8, with its guanidinium group close to the end of
H7. In the 2.3 A˚ resolution structure of carvedilol-bound b1AR-
m23, the side chain of Arg3558.56 is well resolved for the first
time in any structure (Figure 5) and it forms hydrogen bonds
with Ser681.59 and Thr691.60 at the intracellular end of H1. The
hydrogen bonds between H8 and H1 would be expected to
stabilize the receptor, which is substantiated by the fact that
Ser681.59 is one of the six thermostabilizing mutations that facil-
itated crystallization of b1AR-m23 (Serrano-Vega et al., 2008;
Serrano-Vega and Tate, 2009). In the wild-type turkey b1AR,
the equivalent residue to Ser681.59 is Arg681.59 and when this
is mutated to an uncharged residue (Ala) the receptor becomes
more thermostable, presumably because the proximity of
Arg681.59 and Arg3558.56 is electrostatically unfavorable. Muta-
tion of Arg681.59 to Ser increases the thermostability further,
which is consistent with the formation of the hydrogen bond to
Arg3558.56 observed in the structure with bound carvedilol.
Increased thermostability of b1AR is likely to reflect a decrease
in the global flexibility of the whole receptor. Thus, changes in
thermostability due tomutations at the H1-H8 interface suggests
that analogous changes in homologous receptors may also
change the global dynamics of these receptors. These observa-
tions in the avian b1AR probably apply to human b1AR and b2AR
as the equivalent residues to Arg681.59 are Lys851.59 and
Lys601.59. Thus, the Arg/Gly389 polymorphism in human b1AR
will similarly alter the packing between H1 and H8, which could
result in changes in the dynamics of the receptor, with the barrier
to formation of the R* state perhaps being lower in the b1AR-
Arg389 variant. This is indeed what has been observed pharma-
cologically and biochemically in a number of studies (Liggett
et al., 2006; Rochais et al., 2007; Swift et al., 2008). It has also
been observed that carvedilol is a more efficient inverse agonist
of the human b1AR-Arg389 isoform than are metoprolol and
bisoprolol (Rochais et al., 2007), two beta blockers that do not
have extensions at their amine ends (see Figure 1). These
findings have led to interest in the potential of genetically tar-
geted therapies for heart failure with bucindolol or carvedilol
(DeGeorge and Koch, 2007; Pleger and Koch, 2006). A similar
polymorphism at Trp641.59 in the human b3AR has also been
observed, where substitution of Trp for Arg has been associated
with compromised activity of the receptor and, consequently,
increased obesity (Kimura et al., 2000; Kurokawa et al., 2008;
Pie´tri-Rouxel et al., 1997).Structure 20Conclusions
The structures of b1AR bound to either bucindolol or carvedilol
show that both of these ligands make additional contacts to
helices 2, 3, and 7 and extracellular loop 2 compared to other
structurally characterized bAR inverse agonists. Overall the
structures show no conformational change when compared to
other b1AR antagonist structures, but it is probable that the addi-
tional interactions in the extended ligand binding pocket might
increase the likelihood of subtle conformational changes that
result in enhanced arrestin binding and G protein-independent
signaling. The fact that both bucindolol and carvedilol bind to
b1AR in a similar manner to other bAR G protein antagonists,
yet they can stimulate signaling via G protein-independent path-
ways while apparently inhibiting G protein coupling, strongly
supports the contention that arrestin can bind to a different
conformation of the receptor to that bound by G proteins.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization
The turkey (Meleagris gallopavo) b1AR construct, b44-m23, contains six ther-
mostabilizing point mutations, two point mutations which improve receptor
expression and homogeneity, and truncations at the N terminus, inner loop 3
and C terminus (Warne et al., 2011). Baculovirus expression and purification
were all performed as described previously, with the detergent exchanged
to Hega-10 (0.35%) on the alprenolol Sepharose affinity column (Warne
et al., 2003, 2008, 2009, 2011). Purified receptor was competitively eluted
from the alprenolol Sepharose column with either bucindolol or carvedilol,
but this was difficult because of the poor solubility of the ligands. Ligands
were added to saturation from 20 mg/ml DMSO stock solutions to the elution
buffer (10mMTris-HCl [pH 7.4], 100mMNaCl, 0.1mMEDTA, 0.35%Hega-10)
with rapid stirring. The approximate final concentrations of the ligands in the
elution buffer were 10 mM for carvedilol and 50 mM for bucindolol. Receptor
was concentrated to 20 mg/ml in 10 mM Tris-HCl (pH 7.6), 100 mM NaCl,
0.1 mM EDTA, 0.35% Hega-10. Before crystallization, Hega-10 was added
to 0.5%. Crystals were grown at 4C by vapor diffusion in sitting drops with
150 nl receptor + 150 nl precipitant (0.1 M bicine [pH 9.0], 25% PEG 600 in
both cases) and cryoprotected by addition of 60% PEG 600 for 1 min before
mounting on Hampton CrystalCap HT loops and cryocooling in liquid nitrogen.
Data Collection, Structure Solution, and Refinement
For both complexes, diffraction data were collected from a single cryocooled
crystal (100 K) at the European Synchrotron Radiation Facility, Grenoble,
France, with a Mar 225 CCD detector on beamline ID23-2 (wavelength,
0.8726 A˚) using a 10 mm focused beam. The microfocus beam was required
for the location of the best diffracting parts of crystals, as well as allowing
wedges of data (20–80) to be collected from different positions on the crystal., 841–849, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 847
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Biased Agonist-Bound b1-Adrenoceptor StructuresFor the b1AR crystals grown in the presence of bucindolol or carvedilol, 9 or 16
wedges of data from single crystals were merged, respectively. Images were
processed with MOSFLM (Leslie, 2006) and SCALA (Evans, 2006). Both struc-
tures were solved by molecular replacement with PHASER using the b1AR44-
m23 structurewith the agonist carmoterol bound (PDBcode 2Y02) as a starting
model (McCoy et al., 2007). Refinement, rebuilding and validation were carried
out with REFMAC5 (Murshudov et al., 1997), COOT (Emsley and Cowtan,
2004) and MOLPROBITY (Davis et al., 2007). Noncrystallographic symmetry
restraints were applied as appropriate between the two monomers in the
asymmetric unit for both structures, using the electron density maps and Rfree
values to judge which residues should be excluded. The two independent
copies of the receptor in the asymmetric unit are very similar for the bucindolol
complex, although the ligand density was better defined for monomer A. In the
carvedilol complex, there is a distortion of the ligand binding pocket in mono-
mer A due to lattice contacts and monomer B represents the more physiolog-
ically relevant conformation.ACCESSION NUMBERS
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